PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP ...
Developers are increasingly exploring non-viral gene therapy delivery methods as safety concerns over viral vectors grow. Approaches such as lipid nanoparticles, Sleeping Beauty transposons, and ...
Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
Over the past decade, non-viral DNA template delivery has been used with engineered nucleases to target single-stranded DNA sequences in hematopoietic stem and progenitor cells (HSPCs). While ...
Polymer-based gene delivery systems represent a promising class of non-viral vectors, offering significant advantages in safety, structural versatility, biodegradability, and the potential for ...
Heart diseases are still the number one cause of death worldwide. According to the World Health Organization, cardiovascular diseases led to the deaths of about 9.8 million people in 2022 alone, ...
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results